You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023198020
Dec 20233108
Jan 20244003
Feb 20243804
Mar 20245608
Apr 20244209
May 20244407
Jun 20242403
Jul 20241602
Aug 20244206
Sep 20243605
Oct 20242405
Nov 202424012
Dec 20242206
Jan 20251707
Feb 20251003
Mar 2025208
Apr 2025007
May 2025004
Jun 2025005
Total6660132